Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

The approval of trastuzumab emtansine (T-DM1) was conducted without pertuzumab as previous therapy. Efficacy data on T-DM1 following pertuzumab treatment are therefore limited. This study explores this issue in a real-world setting. Within the prospective PRAEGNANT (Prospective Academic Translationa...

Full description

Bibliographic Details
Main Authors: Laura L. Michel, Andreas D. Hartkopf, Peter A. Fasching, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Bernhard Volz, Hanna Huebner, Pauline Wimberger, Carsten Hielscher, Christoph Mundhenke, Christian Kurbacher, Rachel Wuerstlein, Michael Untch, Friedrich Overkamp, Jens Huober, Wolfgang Janni, Florin-Andrei Taran, Michael P. Lux, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Tanja N. Fehm
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
advanced breast cancer
metastatic
chemotherapy
HER2 c-erbB2
HER2/neu
trastuzumab
Online Access:https://www.mdpi.com/2072-6694/12/10/3021

Internet

https://www.mdpi.com/2072-6694/12/10/3021

Similar Items